EFFECTIVENESS AND SAFETY OF VELAGLUCERASE ALFA IN TREATMENT OF GAUCHER DISEASE TYPE 1 (ACCORDING TO INTERNATIONAL STUDIES)
https://doi.org/10.15690/pf.v11i6.1215
Abstract
The article is dedicated to modern approaches to treatment of Gaucher’s disease. The authors list the primary aspects of the disease and present data on the origin and introduction of pathogenetic enzyme replacement therapy to clinical practice. Review of international clinical studies demonstrates high effectiveness and safety of long-term enzyme replacement therapy with velaglucerase alfa in patients with confirmed type I Gaucher’s disease.
About the Authors
O. S. Gundobina
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
G. B. Movsisyan
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
E. V. Komarova
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
L. S. Namazova-Baranova
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
References
1. Gundobina O.S., Komarova E.V., Namazova-Baranova L.S., Gevorkyan A.K., Movsisyan G.B. Gaucher's disease in children. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2013; 10 (3): 72−75.
2. Movsisyan G.B., Gundobina O.S., Namazova-Baranova L.S. Evaluating the effectiveness of enzyme replacement therapy in children with Gaucher disease according to international studies. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2014; 11 (3): 80−84.
3. Elstein D. et al. Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: Early Access Program results from Jerusalem. Blood Cells Mol Dis. 2012; 48: 45–50.
4. Zimran A. et al. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase. Am J Hematol. 2013; 88: 172−178.
5. Gonzalez D.E. et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study. Am J Hematol. 2013; 88: 166−171.
6. Ben Turkia H. et al. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. Am J Hematol. 2013; 88: 179−184.
7. Pastores G.M. et al. Long-term velaglucerase alfa of enzyme replacement therapy in children with type 1 Gaucher disease. Poster presented at the SSIEM Annual Symposium, September 2–5. Innsbruck, Austria. 2014.
8. Giraldo P. et al. Safety and efficacy of velaglucerase alfa in children with type 1 Gaucher disease: 2-year experience. Poster presented at the American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting, March 27–31. Charlotte, North Carolina, USA. 2012.
9. Grabowski G.A. et al. Linear growth over 2 years of velaglucerase alfa therapy in children with type 1 Gaucher disease previously treated with imiglucerase. Poster presented at the American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting, March 27–31. Charlotte, North Carolina, USA. 2012.
10. Pastores G.M. et al. A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability. Genet Med. 2014; 16 (5): 359−366.
11. Goker-Alpan O. et al. Safety of velaglucerase alfa in type 1 Gaucher disease patients with anti-imiglucerase antibodies. Poster presented at the American Society of Human Genetics (ASHG) 62-nd Annual meeting, November 6–10. San Francisco, CA, USA. 2012.
Review
For citations:
Gundobina O.S., Movsisyan G.B., Komarova E.V., Namazova-Baranova L.S. EFFECTIVENESS AND SAFETY OF VELAGLUCERASE ALFA IN TREATMENT OF GAUCHER DISEASE TYPE 1 (ACCORDING TO INTERNATIONAL STUDIES). Pediatric pharmacology. 2014;11(6):52-55. (In Russ.) https://doi.org/10.15690/pf.v11i6.1215
Views:
844
Email this article 